


11/18/07

"Express Mail" Mailing Label No. EL703798800US

AF
IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: David A. Cheresh et al.)
Application No. 09/538,248)
Filed: March 29, 2000) Group Art Unit: 1652
For: METHODS USEFUL FOR TREATING)
VASCULAR LEAKAGE AND EDEMA)
USING SRC OR YES TYROSINE)
KINASE INHIBITORS)
Examiner: Rebecca E. Prouty) Attorney Docket No. TSRI 651.3

May to
be entered
by
RGE

RESPONSE UNDER RULE 116

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This communication is submitted in response to the Office Action dated August 13, 2004 on the above-identified application.

Claims 1-4, 17-20, 32 and 33 are currently under consideration.

Claims 1-3 and 17-20 specify that the pharmaceutical composition comprises an inhibitor of human c-Src tyrosine kinase. Claim 4 is dependent on claim 3 and specifies that the inhibitor is PP1.

Claim 32 is dependent on claim 18 and specifies that the inhibitor is PP2.

Claim 33 is dependent on claim 3 and specifies that the inhibitor is PP2.

The rejection of claims 1, 2, 17 and 18 under 35 U.S.C. 102(e) as allegedly being anticipated by US 6,001,839 ("Calderwood Patent") is not warranted. As pointed out in prior Response, the Calderwood Patent teaches that certain pyrrolopyrimidine compounds, not pyrazolopyrimidine compounds, are useful for treating VEGF mediated edema. This patent only generally mentions the Src family of tyrosine kinases along with other classes of kinases (i.e., the Syk and Janus families, at col. 12, line 53, through col. 13, line 9). The present claims are limited to methods and articles of manufacture including inhibitors of